Scholarlink

Objective <p>To investigate the pharmacodynamic and pharmacokinetic interactions between Shenqi Oral Liquid (SQ) and atorvastatin (ATV) in hyperlipidemic rats, explore the impact of SQ on ATV-related transporters and metabolic enzymes, the potential implications for the safety and rationality of their combined administration based on pharmacodynamic, pharmacokinetic, transporter, and metabolic enzyme data.</p> Methods <p>Hyperlipidemic rats were induced using a high-fat diet and randomized according to serum total cholesterol levels using a randomized block design into model, ATV (10 mg/kg), SQ (0.68, 1.68, 3.38 g/kg), and combination groups, and treated for 4 weeks. Serum lipid profiles, liver histopathological changes, pharmacokinetic parameters of ATV, mRNA expression levels of transporters (including Bcrp, Mrp2, etc.) and metabolic enzymes (CYP2C11, CYP3A2), enzyme activities, as well as the effects of SQ’s active ingredients were assessed using quantitative PCR, cocktail probe assays, and primary hepatocyte studies.</p> Results <p>The combination therapy significantly reduced serum lipid levels and improved liver histology, as evidenced by a more organized cellular structure and reduced accumulation of lipid droplets. SQ significantly increased systemic exposure of ATV metabolites, elevating the maximum plasma concentration (C<sub>max</sub>) and area under the curve from time 0 to time t (AUC<sub>0-t</sub>) of o-ATV by 97.02% and 119.01%, and of p-ATV by 73.22% and 63.39%, respectively (all <i>P</i>&lt;0.05). SQ downregulated the expressions of Bcrp and Mrp2 in the jejunum and Oatp2b1, Bcrp, and Mrp2 in the ileum, while upregulating Oatp1b2 and CYP3A2 in the liver (all <i>P</i>&lt;0.05). Additionally, it enhanced the enzymatic activities of CYP2C11 and CYP3A2, as shown by significantly reduced AUC<sub>0-∞</sub> of omeprazole (<i>P</i>&lt;0.01) and AUC<sub>0-t</sub> of midazolam (<i>P</i>&lt;0.05). Notably, tangshenoside I, lobetyolin, and ononin were found to promote CYP3A2 mRNA expression (<i>P</i>&lt;0.05).</p> Conclusions <p>SQ synergizes with ATV in lipid regulation and hepatoprotection through modulation of drug transporters and metabolic enzymes. These findings suggest that dose adjustment of ATV may be necessary during combination therapy, thereby providing a scientific basis for the rational co-administration of these agents.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Beneficial Herb-Drug Interaction of Shenqi Oral Liquid on Atorvastatin: A Pharmacokinetic and Pharmacodynamic Investigation in Rats with Hyperlipidemia

  • 期刊论文

  • 发表日期：

    2026年4月16日

查看全文
  • Xian-run Hu,
  • Man-lin Li,
  • Wen-kang Liu,
  • Si-tong Zhang,
  • Jin-chun Lei,
  • Jun-yi Wang,
  • Mi-re-yi Bahatijiang,
  • Xue-mei Cheng,
  • Chang-hong Wang

摘要

Objective

To investigate the pharmacodynamic and pharmacokinetic interactions between Shenqi Oral Liquid (SQ) and atorvastatin (ATV) in hyperlipidemic rats, explore the impact of SQ on ATV-related transporters and metabolic enzymes, the potential implications for the safety and rationality of their combined administration based on pharmacodynamic, pharmacokinetic, transporter, and metabolic enzyme data.

Methods

Hyperlipidemic rats were induced using a high-fat diet and randomized according to serum total cholesterol levels using a randomized block design into model, ATV (10 mg/kg), SQ (0.68, 1.68, 3.38 g/kg), and combination groups, and treated for 4 weeks. Serum lipid profiles, liver histopathological changes, pharmacokinetic parameters of ATV, mRNA expression levels of transporters (including Bcrp, Mrp2, etc.) and metabolic enzymes (CYP2C11, CYP3A2), enzyme activities, as well as the effects of SQ’s active ingredients were assessed using quantitative PCR, cocktail probe assays, and primary hepatocyte studies.

Results

The combination therapy significantly reduced serum lipid levels and improved liver histology, as evidenced by a more organized cellular structure and reduced accumulation of lipid droplets. SQ significantly increased systemic exposure of ATV metabolites, elevating the maximum plasma concentration (Cmax) and area under the curve from time 0 to time t (AUC0-t) of o-ATV by 97.02% and 119.01%, and of p-ATV by 73.22% and 63.39%, respectively (all P<0.05). SQ downregulated the expressions of Bcrp and Mrp2 in the jejunum and Oatp2b1, Bcrp, and Mrp2 in the ileum, while upregulating Oatp1b2 and CYP3A2 in the liver (all P<0.05). Additionally, it enhanced the enzymatic activities of CYP2C11 and CYP3A2, as shown by significantly reduced AUC0-∞ of omeprazole (P<0.01) and AUC0-t of midazolam (P<0.05). Notably, tangshenoside I, lobetyolin, and ononin were found to promote CYP3A2 mRNA expression (P<0.05).

Conclusions

SQ synergizes with ATV in lipid regulation and hepatoprotection through modulation of drug transporters and metabolic enzymes. These findings suggest that dose adjustment of ATV may be necessary during combination therapy, thereby providing a scientific basis for the rational co-administration of these agents.